The following info may help
http://www.biomira.com/patients/vacc...plained/BLP25/ BLP25 Liposome Vaccine for Lung Cancer
Lung cancer continues to be the leading cause of cancer-related death among both men and women in North America. Non-small cell lung cancer is the most common type of lung cancer, accounting for about 80 per cent of all cases.
Biomira's investigational BLP25 offers an innovative approach to treating the disease and potentially prolonging life. It is designed to induce a T-cell immune response to the cancer. Similar to Biomira's other cancer vaccines, BLP25 does not appear to have any significant side effects.
BLP25 is a synthetic 25-amino acid sequence of the cancer-associated marker MUC-1 encapsulated in a specially designed liposomal delivery system. Liposomes, which are fat droplets smaller than red blood cells, are believed to enhance immune recognition of cancer cells.
In September 2004, the FDA granted fast track status to the investigation of L-BLP25 for its proposed used in the treatment of NSCLC.
Trial participation for BLP25 is closed.